Treatment forms of house dust mites allergens intended for allergen-specific immunological therapy

Cover Page

Cite item

Full Text

Abstract

BACKGROUND: The growth of allergic diseases dictates the necessity to develop new forms of therapeutic allergens since therapy with native water-salt extracts of allergens is unsafe and convenient. The risk of systemic side effects during allergen-specific immunotherapy sets the task for researchers to create modern therapeutic forms of allergens with high immunogenic and low allergenic activity. Our laboratory has been developing preparations for the diagnosis and treatment of house dust mites allergies for many years.

AIMS: To create modern therapeutic forms of allergen preparations from house dust mites of the genus Dermatophagoides that are intended for allergen-specific immunotherapy

MATERIALS AND METHODS: Physicochemical and immunobiological methods, such as electrophoresis in polyacrylamide gel, micropoint immunoblot, solid-phase enzyme-linked immunosorbent assay, and the reaction of binding inhibition of allergen-specific immunoglobulin E in the sera of patients were used to study the obtained preparations.

RESULTS: A technology has been developed to obtain a granular dosage form of a mixed allergen from Dermatophagoides pteronyssinus and Dermatophagoides farinae mites for sublingual use. This treatment form has successfully passed preclinical tests, has a pronounced immunogenic activity, and reduced allergenicity, and is convenient for pediatric practice. Allergoids, which are chemically modified preparations, are obtained to reduce allergenicity and increase therapeutic allergen immunogenicity. A succinylated monomeric house dust mites allergoid Dermatophagoides pteronyssinus was created and studied with the National Research Center, Institute of Immunology Federal Medical-Biological Agency of Russia. The study of the immunobiological properties of the obtained preparation showed that the monomeric allergoid has increased immunogenic and decreased allergenic activity contrary to the native water-salt extract.

CONCLUSIONS: The created forms of mite allergens can be used to treat patients who are sensitized to house dust mites of the genus Dermatophagoides after clinical trials.

About the authors

Valentina M. Berzhets

I. Mechnikov Research Institute of Vaccines and Sera

Email: laball@yandex.ru
ORCID iD: 0000-0001-5055-7593
SPIN-code: 9097-0947

Dr. Sci. (Biol.) Professor

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Anna V. Vasilyeva

I. Mechnikov Research Institute of Vaccines and Sera

Author for correspondence.
Email: annaksu@mail.ru
ORCID iD: 0000-0002-7703-2698
SPIN-code: 8351-1808
Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Nina S. Petrova

I. Mechnikov Research Institute of Vaccines and Sera

Email: s.levina2005@yandex.ru
ORCID iD: 0000-0003-2824-1335
SPIN-code: 3151-1562

Cand. Sci. (Biol.)

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Svetlana V. Khlgatian

I. Mechnikov Research Institute of Vaccines and Sera

Email: svetkh@gmail.com
ORCID iD: 0000-0001-8354-7682
SPIN-code: 1476-4605

Dr. Sci. (Biol.)

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Stanislava Yu. Petrova

I. Mechnikov Research Institute of Vaccines and Sera

Email: petrovastanislava@yandex.ru
ORCID iD: 0000-0003-3034-0148
SPIN-code: 7268-6944

MD, Cand. Sci. (Med.)

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Olga Yu. Emelyanova

I. Mechnikov Research Institute of Vaccines and Sera

Email: laball@yandex.ru
ORCID iD: 0000-0002-8071-5385
SPIN-code: 1721-6502

Cand. Sci. (Biol.)

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

Lyubov N. Nesterenko

I. Mechnikov Research Institute of Vaccines and Sera

Email: lnnesterenko3001@gmail.com
ORCID iD: 0000-0002-3825-3906
SPIN-code: 6819-7980

Cand. Sci. (Chem.)

Russian Federation, 5a, Malyi Kazennyi lane, Moscow, 105064

References

  1. Grieger JA, Clifton VL, Tuck AR, et al. In utero Programming of Allergic Susceptibility. Int Arch Allergy Immunol. 2016;169(2):80–92. doi: 10.1159/000443961
  2. Makarova SG, Lavrova TE, Vishnyova EA, et al. Primary prevention as an effective response. Pediatric Pharmacology. 2015;12(1):67–73. (In Russ).
  3. Kurbacheva OM, Kozulina IE. One again about allergy: Epidemiology and the essentials of pathogenesis, diagnosis, and therapy. Russian Rhinology. 2014;22(4):46–50. (In Russ). doi: 10.17116/rosrino201422446-50
  4. Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011;32(9):402–411. doi: 10.1016/j.it.2011.06.006
  5. Fradkin VA. Diagnostic and therapeutic allergens. Moscow: Medicine; 1990. 255 p. (In Russ).
  6. Ibragimov AN, Bikmullin AG, Sataeva DA, et al. Chromatographic methods for protein purification. Study guide. Kazan: FGAOU VPO KFU; 2013. 48 р. (In Russ).
  7. Struchkova IV, Kalyasova EA. Theoretical and practical foundations of protein electrophoresis in polyacrylamide gel. Electronic teaching aid. Nizhny Novgorod: Nizhny Novgorod State University; 2012. 60 р. (In Russ).
  8. A guide to protein blotting. Tips and tricks. Merck Millipore. 6th ed. [Internet]. (In Russ). Available from: https://docplayer.com/56000512-Rukovodstvo-po-blottingu-belkov-sovety-i-priemy.html. Accessed: 15.10.2021.
  9. Berzhets VM, Koreneva SV, Khlgatian SV, et al. Study of the specific activity of the granulated form of the mixed-allergen from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae for oral immunotherapy. Immunopathology, Allergology, Infectology. 2019;(2):56–61. (In Russ). doi: 10.14427/jipai.2019.2.56
  10. Trial J, Christian V, Vibeke BC. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725. doi: 10.1001/jama.2016.3964
  11. Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60(1):133. doi: 10.1111/j.1398-9995.2004.00616.x
  12. Cevdet O, Didem Y, Izlem G, et al. Efficacy of long‐term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite‐allergic children with asthma. Pediatr Allergy Immunol. 2007;18(6):508–515. doi: 10.1111/j.1399-3038.2007.00549.x
  13. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Healthe Technology Assessmen. 2013;17(27):1–322. doi: 10.3310/hta17270
  14. Cui L, Li J, Li Y, Xia Z. International archives of allergy and immunology long-term efficacy of sublingual mite immunotherapy in monosensitized and polysensitized children with allergic rhinitis: a 7-year prospective study. Int Arch Allergy Immunol. 2019;180(2):144–149. doi: 10.1159/000500524
  15. Petrovа SYu, Berzhets VM, Petrovа NS, et al. Future prospect of allergen therapeutic forms. From abstract problems towards specific solutions. Immunopathology, Allergology, Infectology. 2018;(1):40–47. (In Russ). doi: 10.14427/jipai.2018.1.40
  16. Babakhin AA, Laskin AA, Smirnov VV, et al. Monomeric allergoid from house dust mite Dermatophagoides pteronyssinus: immunological properties Russian Journal of Allergy. 2016;(4-5):29–36. (In Russ).
  17. Babakhin AA, Andreev SM, Babievsky KK, et al. Allergen-specific immunotherapy with chemically modified allergens. Part 1. Allergenicity and immunogenicity of succinylated allergen and its complexes with the immunomodulator polyoxidonium. Physiology and Pathology of the Immune System. 2011;(3):7–37. (In Russ).
  18. Laskin AA, Babakhin AA, Andreev SM, et al. Allergenicity and immunogenicity of modified extract from house dust mite Dermatophagoides pteronyssinus. Russian Immunological Journal. 2016;10(2):193–195. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of phenol-free water-salt allergen (PWSA).

Download (72KB)

Copyright (c) 2021 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies